Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine

AIDS

Volumn 15, Issue 18, 2001, Pages 2469-2470

  Barreiro, P ^a   Soriano, V ^a   Valencia, E ^a   Diaz B ^a   Gonzalez Lahoz J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA;

ABDOMINAL DISCOMFORT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; NEUROPATHY; PANCREATITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN MANIFESTATION; THROMBOCYTOPENIA; VIRUS REPLICATION;

ANTI-HIV AGENTS; DIDANOSINE; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; INCIDENCE; PANCREATITIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035824723     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200112070-00024     Document Type: Letter

References (7)

1. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
2. Structured antiretroviral therapy interruption as a form of immune-based therapy in HIV-infection
3. Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy
4. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
5. Randomized trial of continued IDV/ZDV3TC vs switch to IDV/ddl/d4T or IDV/ddl/ d4T+ hydroxyurea in patients with viral suppression
6. The role of hydroxiurea in the treatment of HIV infection
7. Alpha International Coordinating Committee The alpha trial European/Australian randomised double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease